Association between atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis.

Association between atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis.
复制标题

动脉粥样硬化与阿尔茨海默病之间的关联:系统评价和荟萃分析。

DOI:
10.1002/brb3.1601
复制
发表时间:
2020
期刊:
Brain Behav
影响因子:
--
通讯作者:
Tang Yi
Tang Yi
中科院分区:
其他
文献类型:
--
作者:
Xie Beijia;Shi Xinrui;Xing Yi;Tang Yi

文献摘要

相似文献

为了评价动脉粥样硬化与阿尔茨海默病(AD)的关系,我们对AD患者和非AD对照者颈动脉内膜中层厚度(CIMT)和动脉粥样硬化患病率的差异进行了系统回顾和Meta分析。方法人工检索PubMed、Embase、科克伦图书馆、和CNKI(中国国家知识基础设施)根据PRISMA的数据,(系统评价和Meta‐分析的首选报告项目)指南。结果最终分析中包括13项研究,7项研究的平均CIMT数据(610例和417例对照)和10项研究报告动脉粥样硬化的患病率(1,698例和6,452例对照)。与对照组相比,AD组CIMT显著增高(总体标准均数差= 0.94; 95%CI,0.48-1.40;p<0.0001),动脉粥样硬化患病率增加(OR = 1.46; 95%CI,1.26-1.68;p<0.0001)。CIMT可能是预测AD风险和评估血管负担的有用标志物。这一发现对未来可能的AD预防和治疗也很重要。
BackgroundTo evaluate the relationship between atherosclerosis and Alzheimer's disease (AD), we conducted a systematic review and meta‐analysis to study the difference of carotid intima–media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non‐AD controls.MethodsThe studies on the association between atherosclerosis and AD were manually searched in PubMed, Embase, Cochrane Library, and CNKI (China National Knowledge Infrastructure) spanned to September 2018 according to PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines.ResultsThirteen studies were included in the final analysis, seven studies with data on the mean CIMT (610 cases and 417 controls) and ten studies reporting on the prevalence of atherosclerosis (1,698 cases and 6,452 controls). Compared with controls, AD group showed a significantly higher CIMT (overall standard mean difference = 0.94; 95% CI, 0.48–1.40;p< .0001) and an increased prevalence of atherosclerosis (OR = 1.46; 95% CI, 1.26–1.68;p< .0001).ConclusionsAtherosclerosis is significantly associated with AD. CIMT might be a useful marker to predict the risk of AD and assess the vascular burden. The finding is also important for possible prevention and treatment of AD in the future.